[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335140-105":59,"doc-detail-335140-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cumulative-incidence-estimates-for-solid-tumors-after-hct-in-the-cibmtr-and-california-cancer-registry-research","Cumulative incidence estimates for solid tumors after HCT in the CIBMTR and California Cancer Registry - Research","","Cumulative incidence estimates for solid subsequent neoplasms (SNs) after hematopoietic cell transplantation (HCT) are evaluated by linking the CIBMTR cohort with California Cancer Registry (CCR) data. The study examines SN ascertainment completeness reported to CIBMTR alone versus combined with CCR from 1991–2018, accounting for competing death risk. Among 18,450 linked patients, cumulative incidence at 10 years increases from 4.0% (CIBMTR only) to 5.3% (CCR only) and 6.3% (both). Patterns are consistent across allogeneic and autologous recipients, supporting improved follow-up risk evaluation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cumulative-incidence-estimates-for-solid-tumors-after-hct-in-the-cibmtr-and-california-cancer-registry-research/335140/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cumulative-incidence-estimates-for-solid-tumors-after-hct-in-the-cibmtr-and-california-cancer-registry-research/335140.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why did the study link CIBMTR with the California Cancer Registry (CCR)?","Question",{"text":112,"@type":113},"To assess how complete solid subsequent neoplasm (SN) ascertainment is when using CIBMTR alone versus combining CIBMTR with comprehensive CCR cancer registry data.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What time period and cohort were analyzed?",{"text":117,"@type":113},"The analysis used a cohort of 18,450 CIBMTR patients linked to CCR, evaluating SN reporting completeness for transplants from 1991 to 2018.",{"name":119,"@type":110,"acceptedAnswer":120},"How did cumulative incidence estimates differ by data source at 10 years after HCT?",{"text":121,"@type":113},"At 10 years following a first HCT, cumulative incidence was 4.0% using CIBMTR only, 5.3% using CCR only, and 6.3% when both sources were combined, accounting for competing risk of death.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335140,1790218778,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","REGULAR ARTICLE  \nCumulative incidence estimates for solid tumors after HCT in the CIBMTR and California Cancer Registry  \nSara J. Schonfeld, 1 Bryan Valcarcel, 1 Christa L. Meyer,2 Bronwen E. Shaw,3 Rachel Phelan,3, 4 J. Douglas Rizzo,3 Ann Brunson,5 Julianne J. P. Cooley,6 Renata Abrahão,5 Ted Wun,5, 6 Shahinaz M. Gadalla, 1 Eric Engels, 1 Paul S. Albert, 1 Rafeek Yusuf,2 Stephen R. Spellman,2 Rochelle E. Curtis, 1 Jeffery J. Auletta,2, 7 Lori Mufﬂy,8 Theresa H. M. Keegan,5, 6 and Lindsay M. Morton 1  \n1 Division of Cancer Epidemiology and Genetics, National Institutes of Health, Department of Health and Human Services, National Cancer Institute, Bethesda, MD; 2 Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, MN; 3 Department of Medicine, Center for International Blood and Marrow Transplant Research and 4 Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI; 5 Division of Hematology and Oncology, Center for Oncology and Hematology Outcomes Research and Training and 6 California Cancer Reporting and Epidemiologic Surveillance Program, University of California Davis Comprehensive Cancer Center, Sacramento, CA; 7 Divisions of Hematology, Oncology & Blood and Marrow Transplant and Infectious Diseases, Nationwide Children’s Hospital, Columbus, OH; and 8 Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, CA  \nKey Points  \n• Linkage of CIBMTR with cancer registry data leads to more complete estimates of cumulative incidence of solid neoplasms following HCT.  \n• This collaborative approach can improve risk factor evaluation to help inform follow-up care practice in the growing HCT survivor population.  \nCompared with the general population, hematopoietic cell transplantation (HCT) survivors are at elevated risk for developing solid subsequent neoplasms (SNs) . The Center for International Blood and Marrow Transplant Research (CIBMTR) is a key resource for quantifying solid SN incidence following HCT, but the completeness of SN ascertainment is uncertain. Within a cohort of 18 450 CIBMTR patients linked to the California Cancer Registry (CCR), we evaluated the completeness of solid SN data reported to the CIBMTR from 1991 to 2018 to understand the implications of using CIBMTR data alone or combined with CCR data to quantify the burden of solid SNs after HCT. We estimated the cumulative incidence of developing a solid SN, accounting for the competing risk of death. Within the cohort, solid SNs were reported among 724 patients; 15.6% of these patients had an SN reported by CIBMTR only, 36.9% by CCR only, and 47.5% by both. The corresponding cumulative incidence of developing a solid SN at 10 years following a ﬁrst HCT was 4.0%(95% conﬁdence interval [CI], 3.5-4.4) according to CIBMTR data only, 5.3%(95% CI, 4.9-5.9) according to CCR data only, and 6.3%(95% CI, 5.7-6.8) according to both sources combined. The patterns were similar for allogeneic and autologous HCT recipients. Linking detailed HCT information from CIBMTR with comprehensive SN data from cancer registries provides an opportunity to optimize SN ascertainment for informing follow-up care practices and evaluating risk factors in the growing population of HCT survivors.  \nIntroduction  \nHematopoietic cell transplantation (HCT) plays an important role as a curative treatment for many malignant and nonmalignant hematologic disorders. Treatment advances and expanded eligibility to  \nSubmitted 17 January 2024; accepted 3 June 2024; prepublished online on Blood Advances First Edition 12 June 2024. [https://doi.org/10.1182/](https://doi.org/10.1182/)[ ](https://doi.org/10.1182/)[bloodadvances.2024012693](bloodadvances.2024012693.)[.](bloodadvances.2024012693.)  \nThe data that support the ﬁndings of this study are available from the California Cancer Registry and the Center for Inte","cbCaitQvV0Rrst8k","https://ap.wps.com/l/cbCaitQvV0Rrst8k","pdf",1765946,11,"English","# Key Points\n# Introduction\n## Background on HCT and solid SN risk\n## Role and limitations of CIBMTR data\n## Rationale for linking with CCR","[{\"question\":\"Why did the study link CIBMTR with the California Cancer Registry (CCR)?\",\"answer\":\"To assess how complete solid subsequent neoplasm (SN) ascertainment is when using CIBMTR alone versus combining CIBMTR with comprehensive CCR cancer registry data.\"},{\"question\":\"What time period and cohort were analyzed?\",\"answer\":\"The analysis used a cohort of 18,450 CIBMTR patients linked to CCR, evaluating SN reporting completeness for transplants from 1991 to 2018.\"},{\"question\":\"How did cumulative incidence estimates differ by data source at 10 years after HCT?\",\"answer\":\"At 10 years following a first HCT, cumulative incidence was 4.0% using CIBMTR only, 5.3% using CCR only, and 6.3% when both sources were combined, accounting for competing risk of death.\"}]","Cumulative incidence estimates for solid tumors after HCT in the CIBMTR and California Cancer Registry - Research | PDF",1790009780,28]